KAMALJEET GILL: Open Payments
NPI 1285351528 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,328 in 97 payments from 23 companies in 2025. Trend: 2023 $904 · 2024 $2,049 · 2025 $2,328
Food & beverage: $2,328
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $298 |
| Regeneron Healthcare Solutions, Inc. | 9 | $284 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $235 |
| Lilly USA, LLC | 6 | $230 |
| Amgen Inc. | 17 | $171 |
| Verona Pharma, Inc. | 5 | $150 |
| GlaxoSmithKline, LLC. | 12 | $149 |
| Novo Nordisk Inc | 1 | $125 |
| GENZYME CORPORATION | 4 | $90 |
| United Therapeutics Corporation | 3 | $79 |
Products named: DUPIXENT, TEZSPIRE, MOUNJARO, Ohtuvayre, TRELEGY ELLIPTA, AIRSUPRA, Ozempic, Tyvaso.
Industry payments across CA — which companies pay providers there.
